Department of Dermatology, Gansu Provincial Maternity and Child-care Hospital (Gansu Provincial Central Hospital), Lanzhou, 730000, China.
School of Pharmacy, Faculty of Medicine, Macau University of Science and Technology, Macau SAR, China.
Syst Rev. 2024 Oct 2;13(1):250. doi: 10.1186/s13643-024-02653-7.
Vitiligo is a chronic skin disorder causing depigmentation. There is a lack of evidence-based medical evidence regarding ruxolitinib efficacy and safety for vitiligo.
To assess the efficacy and safety of ruxolitinib cream in the treatment of vitiligo.
The databases of PubMed, Embase, and Cochrane Library were searched. The literature screening was independently conducted by two reviewers.
For continuous variables, weighted mean difference (WMD) along with a 95% confidence interval (CI) was performed. For dichotomous outcomes, we calculated the odds ratios (ORs) or risk ratios (RRs), and their corresponding 95% CIs. The certainty of evidence was evaluated using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE).
Symptoms, quality of life, and safety were evaluated using various measures, including the Facial Vitiligo Area Scoring Index (F-VASI), Total Vitiligo Area Scoring Index (T-VASI), Facial Body Surface Area (F-BAS), Total Body Surface Area (T-BAS) and Treatment-emergent Adverse Events (TEAEs).
Three trials, involving a total of 830 participants from nine countries were included (female 388, 46.7%, male 442, 53.3%). The meta-analysis demonstrated a significant increase in the likelihood of participants achieving F-VASI75 (OR, 4.34 [95% CI 2.67-7.06]; high), F-VASI50 (OR 4.71 [95% CI 3.24-6.84]; high), T-VASI75 (OR 2.78 [95% CI 1.10-7.00]; moderate), and T-VASI50 (OR 4.47 [95% CI 2.52-7.92]; high) when compared ruxolitinib to vehicle. Ruxolitinib was associated with more lowered percentage change of F-VASI scores (MD - 32.79 [95% CI - 36.37 to - 29.21]; moderate), and T-VASI scores (MD - 20.22 [95% CI - 23.11 to - 17.33]; moderate) from baseline compared to vehicle. There may not be a significant difference in the occurrence of TEAEs between ruxolitinib and vehicle (RR 1.46 [95% CI 0.85-2.49]; high).
The findings suggest that ruxolitinib cream holds promise as a treatment option for vitiligo. Further long-term studies are needed to assess its sustained efficacy and safety profile.
PROSPERO CRD42023431112.
白癜风是一种导致色素脱失的慢性皮肤疾病。目前，关于鲁索替尼乳膏治疗白癜风的疗效和安全性，缺乏基于证据的医学证据。
评估鲁索替尼乳膏治疗白癜风的疗效和安全性。
检索了 PubMed、Embase 和 Cochrane 图书馆的数据库。两位评审员独立进行了文献筛选。
对于连续变量，采用加权均数差（WMD）及其 95%置信区间（CI）。对于二分类结局，我们计算了比值比（OR）或风险比（RR）及其相应的 95%CI。使用推荐评估、制定与评价（GRADE）等级评估证据的确定性。
使用各种措施评估症状、生活质量和安全性，包括面部白癜风面积评分指数（F-VASI）、总白癜风面积评分指数（T-VASI）、面部体表面积（F-BAS）、总体表面积（T-BAS）和治疗出现的不良事件（TEAEs）。
共纳入来自 9 个国家的 3 项试验，共 830 名参与者（女性 388 名，占 46.7%；男性 442 名，占 53.3%）。荟萃分析表明，与安慰剂相比，鲁索替尼更有可能使参与者达到 F-VASI75（OR，4.34[95%CI 2.67-7.06]；高）、F-VASI50（OR，4.71[95%CI 3.24-6.84]；高）、T-VASI75（OR，2.78[95%CI 1.10-7.00]；中）和 T-VASI50（OR，4.47[95%CI 2.52-7.92]；高）。与安慰剂相比，鲁索替尼与 F-VASI 评分（MD-32.79[95%CI-36.37 至-29.21]；中）和 T-VASI 评分（MD-20.22[95%CI-23.11 至-17.33]；中）的基线百分比变化降低更明显。鲁索替尼与安慰剂治疗的 TEAEs 发生率可能无显著差异（RR 1.46[95%CI 0.85-2.49]；高）。
研究结果表明，鲁索替尼乳膏有望成为白癜风的一种治疗选择。需要进一步的长期研究来评估其持续疗效和安全性。
PROSPERO CRD42023431112。
